PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C12N 15/867, 15/861, 5/10, 7/01, A61K 48/00, C12N 9/12

A1

(11) International Publication Number: WO 00/56910

(43) International Publication Date: 28 September 2000 (28.09.00)

(21) International Application Number: PCT/GB00/01091

(22) International Filing Date: 22 March 2000 (22.03.00)

(30) Priority Data:
9906615.1 22 March 1999 (22.03.99) GB

(71) Applicant *(for all designated States except US)*: OXFORD BIOMEDICA (UK) LIMITED [GB/GB]; Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: UDEN, Mark [GB/GB]; Flat 2, 17 Sommerfield Road, Finsbury Park, London N4 2JN (GB). MITROPHANOUS, Kyriacos [GR/GB]; 39 Wytham Street, Oxford OX1 4TR (GB).

(74) Agents: HARDING, Charles, Thomas et al.; D Young & Co., 21 New Fetter Lane, London EC4A 1DA (GB).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: RETROVIRAL VECTORS COMPRISING FUNCTIONAL AND NON–FUNCTIONAL SPLICE DONOR AND SPLICE ACCEPTOR SITES

(57) Abstract

A retroviral vector comprises a functional splice donor site (FSDS) and a functional splice acceptor (FSAS) site; wherein the FSDS and the FSAS flank a first nucleotide sequence of interest (NOI); wherein the FSDS is upstream of the FSAS; wherein the retroviral vector is derived from a retroviral pro–vector; wherein the retroviral pro–vector comprises a first nucleotide sequence (NS) capable of yielding the functional splice donor site (FSDS); a second NS capable of yielding the functional splice acceptor site (FSAS); a third NS capable of yielding a non–functional splice donor site (NFSDS); a fourth NS capable of yielding a non–functional splice site (NFSS); wherein the first NS is downstream of the second NS and wherein the third NS and fourth NS are upstream of the second NS; such that after reverse transcription of the retroviral pro–vector at a desired target site the retroviral vector is capable of being spliced.